An Assessment of Burden Associated with Problem Joints in Children and Adults with Moderate or Severe Haemophilia A: Analysis of the CHESS-Paediatrics and CHESS II Cross-sectional Studies

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Date 2025 Jan 13

PMID 39806420

Authors

Paul McLaughlin

Hortensia De la Corte-Rodriguez

Tom Burke

Francis Nissen

Martynas Aizenas

Katya Moreno

Jamie OHara

Affiliations

Soon will be listed here.

Abstract

Background: Clinical research has offered many definitions and fragmented perspectives of joint morbidity in haemophilia. As joint damage, pain and mobility impairment can be present without clinical record of persistent bleeding, a person-centric joint morbidity characterisation remained a priority for the haemophilia community, giving rise to the 'problem joint' concept. As diagnosing and managing joint morbidity is critical, the aim of this study was to analyse the holistic burden of problem joints in people with moderate or severe haemophilia A (HA). Data from the 'Cost of Haemophilia in Europe: a Socioeconomic Survey' (CHESS) cross-sectional studies were used. CHESS-Paediatrics included male paediatric patients (≤ 17 years) with congenital moderate or severe haemophilia, while CHESS II included adult males (≥ 18 years) of any severity. Both studies sought to collect detailed information on the clinical, economic and humanistic burden of haemophilia. Demographics, clinical outcomes, treatment regimen, adherence, physical activity, healthcare resource use and number of problem joints were evaluated and described by HA severity and number of problem joints (none, 1, ≥ 2).

Results: In total, 1171 people with non-inhibitor moderate or severe HA from CHESS-Paediatrics (n = 703) and CHESS II (n = 468) were included in this analysis. Presence of problem joints was more prevalent among CHESS II participants (44%) than in CHESS-Paediatrics (14%). Around two-thirds (67%) of CHESS-Paediatrics and 39% of CHESS II participants received prophylactic factor VIII replacement therapy. The presence of chronic pain was greater in severe HA with ' ≥ 2' problem joints in both cohorts. Clinical symptoms and bleed-related hospitalizations were more prevalent in the presence of problem joints regardless of HA severity in both cohorts.

Conclusions: This analysis of the CHESS population studies has expanded on previous work by examining the relevance of the problem joint measure of haemophilic morbidity and its associated burden. Adverse clinical symptoms and increased bleed-related hospitalizations were observed in the presence of problem joints in both children/adolescents and adults across HA severities. Use of person-centric characterizations of joint morbidity may improve analysis of long-term outcomes and lead to improvements in future haemophilia care.

References

Mulder K, Llinas A . The target joint. Haemophilia. 2004; 10 Suppl 4:152-6. DOI: 10.1111/j.1365-2516.2004.00976.x. View

Iorio A, Stonebraker J, Chambost H, Makris M, Coffin D, Herr C . Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019; 171(8):540-546. DOI: 10.7326/M19-1208. View

Rodriguez-Merchan E . Musculoskeletal complications of hemophilia. HSS J. 2009; 6(1):37-42. PMC: 2821487. DOI: 10.1007/s11420-009-9140-9. View

Witkop M, Lambing A, Nichols C, Munn J, Anderson T, Tortella B . Interrelationship between depression, anxiety, pain, and treatment adherence in hemophilia: results from a US cross-sectional survey. Patient Prefer Adherence. 2019; 13:1577-1587. PMC: 6759218. DOI: 10.2147/PPA.S212723. View

Witkop M, Neff A, Buckner T, Wang M, Batt K, Kessler C . Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia. 2017; 23(4):556-565. DOI: 10.1111/hae.13214. View

Blanchette V, Key N, Ljung L, Manco-Johnson M, van den Berg H, Srivastava A . Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12(11):1935-9. DOI: 10.1111/jth.12672. View

OHara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C . The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018; 16(1):84. PMC: 5932770. DOI: 10.1186/s12955-018-0908-9. View

Rodriguez-Santana I, DasMahapatra P, Burke T, Hakimi Z, Bartelt-Hofer J, Nazir J . Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study. Orphanet J Rare Dis. 2022; 17(1):150. PMC: 8981697. DOI: 10.1186/s13023-022-02301-0. View

Donadel-Claeyssens S . Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia. 2006; 12(2):124-7. DOI: 10.1111/j.1365-2516.2006.01202.x. View

10.

Peyvandi F, Tavakkoli F, Frame D, Quinn J, Kim B, Lawal A . Burden of mild haemophilia A: Systematic literature review. Haemophilia. 2019; 25(5):755-763. PMC: 6852304. DOI: 10.1111/hae.13777. View

11.

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe S . WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26 Suppl 6:1-158. DOI: 10.1111/hae.14046. View

12.

Fischer K, van der Bom J, Mauser-Bunschoten E, Roosendaal G, Prejs R, de Kleijn P . The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002; 99(7):2337-41. DOI: 10.1182/blood.v99.7.2337. View

13.

Mancuso M, Holstein K, ODonnell J, Lobet S, Klamroth R . Synovitis and joint health in patients with haemophilia: Statements from a European e-Delphi consensus study. Haemophilia. 2023; 29(2):619-628. DOI: 10.1111/hae.14734. View

14.

OHara J, Noone D, Jain M, Pedra G, Landis S, Hawes C . Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A. Haemophilia. 2021; 27(6):938-946. DOI: 10.1111/hae.14302. View

15.

Ota S, McLimont M, Carcao M, Blanchette V, Graham N, Paradis E . Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia. 2007; 13(1):12-20. DOI: 10.1111/j.1365-2516.2006.01409.x. View

16.

Manco-Johnson M, Nuss R, Funk S, Murphy J . Joint evaluation instruments for children and adults with haemophilia. Haemophilia. 2000; 6(6):649-57. DOI: 10.1046/j.1365-2516.2000.00439.x. View

17.

Ay C, Mancuso M, Matino D, Strike K, Pasta G . The haemophilia joint health score for the assessment of joint health in patients with haemophilia. Haemophilia. 2024; 30(6):1265-1271. PMC: 11659503. DOI: 10.1111/hae.15116. View

18.

Coppola A, Tagliaferri A, Di Capua M, Franchini M . Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost. 2012; 38(1):79-94. DOI: 10.1055/s-0031-1300954. View

19.

Ferri Grazzi E, Sun S, Burke T, OHara J . The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study. J Blood Med. 2022; 13:505-516. PMC: 9507282. DOI: 10.2147/JBM.S363028. View

20.

OHara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C . The relationship between target joints and direct resource use in severe haemophilia. Health Econ Rev. 2018; 8(1):1. PMC: 5770351. DOI: 10.1186/s13561-018-0185-7. View